Novo Nordisk has unveiled plans to invest more than €100 million in production facilities at its site in Chartres, France, in an effort to meet the increasing worldwide demand for its diabetes medicines.  The new facilities will be built on Novo Nordisk’s existing 31,000 square-meter site in Chartres, which produces a range of the company’s insulin products as well as FlexPen, the world’s most widely used insulin injection device. The products are exported to more than 40 co...